Avid Bioservices, Inc. (CDMO)
- Previous Close
7.32 - Open
7.34 - Bid 7.32 x 100
- Ask 7.36 x 200
- Day's Range
7.29 - 7.68 - 52 Week Range
4.07 - 18.86 - Volume
1,255,084 - Avg. Volume
1,351,842 - Market Cap (intraday)
466.577M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.28 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.25
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
www.avidbio.comRecent News: CDMO
Performance Overview: CDMO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDMO
Valuation Measures
Market Cap
466.58M
Enterprise Value
630.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.41
Price/Book (mrq)
2.59
Enterprise Value/Revenue
4.61
Enterprise Value/EBITDA
-80.57
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.93%
Return on Assets (ttm)
-2.27%
Return on Equity (ttm)
-9.67%
Revenue (ttm)
136.74M
Net Income Avi to Common (ttm)
-17.68M
Diluted EPS (ttm)
-0.28
Balance Sheet and Cash Flow
Total Cash (mrq)
30.71M
Total Debt/Equity (mrq)
108.97%
Levered Free Cash Flow (ttm)
-46.99M
Research Analysis: CDMO
Company Insights: CDMO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CDMO
Daily – Vickers Top Buyers & Sellers for 01/11/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/19/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
CDMO: What does Argus have to say about CDMO?
AVID BIOSERVICES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCDMO: What does Argus have to say about CDMO?
AVID BIOSERVICES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target